FBXL6: A Potential Drug Target and Biomarker (G26233)

Target Name: FBXL6

NCBI ID: G26233

FBXL6

FBXL6: A Potential Drug Target and Biomarker

Follicoblastoma, also known as Wilms tumor, is a type of cancer that affects children. It is a common type of cancer that starts in the cells of the nervous system, specifically in the neural crest cells that give rise to all of the different types of tissue in the body. The most common type of Wilms tumor is the Wilms tumor, which affects the Wilms area of 鈥嬧?媡he brain. Wilms tumors are typically treated with surgery, chemotherapy, and radiation therapy. However, there is a growing interest in using drugs that target specific proteins involved in the development and progression of Wilms tumors. One of these proteins is FBXL6.

FBXL6 is a protein that is expressed in a wide variety of tissues and organs, including brain, heart, and blood vessels. It is a member of the family of the tail-like transmembrane proteins, which are known as tyrosine-protein kinases. FBXL6 is involved in the development and progression of many different types of cancer, including Wilms tumors. It is thought to play a role in the regulation of cell growth, cell division, and survival.

One of the key functions of FBXL6 is its ability to promote the growth and survival of cancer cells. It is often used in cell culture studies to add to the growth of cancer cells, and it has been shown to have a positive effect on the growth of a variety of cancer cells, including Wilms tumor cells.

Another function of FBXL6 is its role in the development of resistance to chemotherapy. Wilms tumor cells are often treated with chemotherapy, but some cells can become resistant to the effects of this treatment. It is thought that FBXL6 may play a role in the development of resistance by promoting the growth and survival of resistant cancer cells.

FBXL6 is also of interest as a potential drug target. Many drugs that are used to treat Wilms tumors work by targeting FBXL6. For example, the drug Vismodeg (nirapidone) is used to treat Wilms tumors because it is a inhibitor of FBXL6. This drug works by inhibiting the activity of FBXL6, which in turn inhibits the growth and survival of Wilms tumor cells.

Another drug that is being studied for its ability to target FBXL6 is the drug IMGN632 (canitumab tucoratulin). This drug is being used in clinical trials to treat Wilms tumors because it is a monoclonal antibody that targets FBXL6. It is thought to work by binding to FBXL6 and inhibiting its activity.

While the use of drugs that target FBXL6 is still in its early stages, it is clear that it has the potential to be a valuable tool in the treatment of Wilms tumors. Further research is needed to fully understand the role of FBXL6 in the development and progression of Wilms tumors, as well as its potential as a drug target.

Protein Name: F-box And Leucine Rich Repeat Protein 6

Functions: Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex

The "FBXL6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXL6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets